{"id":"al3810","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2220486","moleculeType":"Small molecule","molecularWeight":"443.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AL3810 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"AL3810 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:32.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02053636","phase":"PHASE2","title":"A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2013-12","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT01283945","phase":"PHASE1, PHASE2","title":"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2010-07","conditions":"Solid Tumors","enrollment":134},{"nctId":"NCT03992131","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)","status":"TERMINATED","sponsor":"pharmaand GmbH","startDate":"2019-06-28","conditions":"Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma","enrollment":25},{"nctId":"NCT04151563","phase":"PHASE1, PHASE2","title":"A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-04-15","conditions":"Carcinoma, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02135107","phase":"PHASE3","title":"A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2013-09","conditions":"Gastroesophageal Reflux Disease","enrollment":517},{"nctId":"NCT04042116","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor","status":"SUSPENDED","sponsor":"Clovis Oncology, Inc.","startDate":"2019-07-29","conditions":"Advanced Solid Tumor, Gynecologic Cancer","enrollment":227},{"nctId":"NCT02202746","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-09-09","conditions":"Breast Cancer, Metastatic Breast Cancer, MBC","enrollment":178},{"nctId":"NCT04254471","phase":"PHASE2, PHASE3","title":"This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients","status":"UNKNOWN","sponsor":"Haihe Biopharma Co., Ltd.","startDate":"2019-11-14","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":313},{"nctId":"NCT02109016","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-04","conditions":"Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC","enrollment":18},{"nctId":"NCT02747797","phase":"PHASE2","title":"Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations","status":"WITHDRAWN","sponsor":"Teresa Helsten, MD","startDate":"2017-04","conditions":"Advanced Cancer","enrollment":""},{"nctId":"NCT03260179","phase":"PHASE1","title":"Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810","status":"UNKNOWN","sponsor":"Haihe Biopharma Co., Ltd.","startDate":"2017-08-31","conditions":"Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT03117101","phase":"PHASE1","title":"Study of the AL3810 in the Treatment of Advanced Solid Tumor","status":"COMPLETED","sponsor":"Haihe Biopharma Co., Ltd.","startDate":"2014-03","conditions":"Advanced Solid Tumors","enrollment":17},{"nctId":"NCT01398410","phase":"PHASE2, PHASE3","title":"Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-12","conditions":"Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin","enrollment":405},{"nctId":"NCT01397448","phase":"PHASE2, PHASE3","title":"Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-07","conditions":"Gastric or Duodenal Ulcers Caused by Low-dose Aspirin","enrollment":472},{"nctId":"NCT01089543","phase":"PHASE2","title":"A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Functional Dyspepsia","enrollment":338},{"nctId":"NCT01153659","phase":"PHASE1","title":"A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-07","conditions":"Healthy","enrollment":90},{"nctId":"NCT01085708","phase":"PHASE1","title":"A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Healthy","enrollment":16},{"nctId":"NCT01085695","phase":"PHASE1","title":"Study of E3810 for Healthy Japanese Male (Under Fasting Condition)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Healthy","enrollment":16},{"nctId":"NCT01202071","phase":"PHASE2","title":"A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00770913","phase":"PHASE2, PHASE3","title":"Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2008-10","conditions":"Refractory Reflux Esophagitis","enrollment":337},{"nctId":"NCT00165672","phase":"PHASE3","title":"A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-05","conditions":"Non-erosive Gastroesophageal Reflux Disease","enrollment":26},{"nctId":"NCT00165646","phase":"PHASE3","title":"A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2004-09","conditions":"Non-erosive Gastroesophageal Reflux Disease","enrollment":288},{"nctId":"NCT00236184","phase":"PHASE3","title":"E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":"Heartburn","enrollment":629},{"nctId":"NCT00236197","phase":"PHASE3","title":"E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":"Heartburn","enrollment":619}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lucitanib","E3810","E-3810"],"phase":"phase_2","status":"active","brandName":"AL3810","genericName":"AL3810","companyName":"Haihe Biopharma Co., Ltd.","companyId":"haihe-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL3810 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}